METABOLIK ASSOTSIRLANGAN JIGAR YOG’ KASALLIGI ATAMASINING TIBBIYOTGA KIRIB KELISHI VA UNING DIAGNOSTIK HAMDA DAVOLASH CHORALARINI TAKOMILLASHTIRISHDAGI AHAMIYATI
##article.subject##:
jigarning assotsirlangan metabolik kasalligi, jigarning yog’ kasalligi, steatogepatit, diagnostika##article.abstract##
Metabolik assotsirlangan jigar yog’ kasalligi (MAJYK)–keng tarqalgan surunkali kasallik bo’lib, moddalar almashinuvi disfunksiyasi asosida yog’ hujayralarining jigarda yuqori darajada akkumulyatsiyasi bilan xarakterlanadi. So’nggi 10 yillikda MAJYK ning aniqlanish darajasi dunyoning ko’plab mintaqalarida 20% dan yuqori ekanligi va bu ko’rsatkichning dinamikada oshib borayotganligi qayd qilish mumkin. Jigarning noalkogol yog’ kasalligi atamasining MAJYK ga o’zgartirilishi ko’p jihatdan bemor va soha mutaxassislariga yengillik yaratdi. Alkogol so’zining tashxisda ishlatilmasligi bemorlar ruhiyatiga salbiy ta’sir ko’rsatmasdan kasallikni to’g’ri qabul qilinishini ta’minlab bergan bo’lsa, MAJYK da virusli, autoimmun gepatit, alkogolli gepatitlarning ham tashxisot uchun qarshi ko’rsatma emasligi keng qamrovli yondashuvga sabab bo’ladi.
Библиографические ссылки
Аляви А.Л., Собирова Г.Н., Абдуллаев А.О., Шадманова Д.А. Пути преодоления трудностей в диагностике неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2023;(10):175-181. https://doi.org/10.31146/1682-8658-ecg-218-10-175-181
Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and Management of Nonalcoholic Fatty Liver Disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. (2022) 28:528–62. doi: 10.1016/j.eprac.2022.03.010
Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, et al. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab. (2017) 19:1630–4. doi: 10.1111/dom.12973
Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. (2020) 158:1999–2014. doi: 10.1053/j.gastro.2019.11.312 21. Day CPJames OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. (1998) 114:842–5. doi: 10.1016/S0016-5085(98)70599-2
Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from "two hit theory" to "multiple hit model". World J Gastroenterol. (2018) 24:2974–83. doi: 10.3748/wjg.v24.i27.2974
Hamraev A.A., Yuldasheva D.Kh. “Prevalence of non-alcoholic fatty liver disease, clinical and laboratory markers”, Central Asian Journal of Medicine, 2022, bet. 112–123.
Liu Z, Suo C, Shi O, Lin C, Zhao R, Yuan H, et al. The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease–related genetic variants. Clin Gastroenterol Hepatol. (2022) 20:e855–75. doi: 10.1016/j.cgh.2020.12.033
Spearman CW, Afihene M, Betiku O, Bobat B, Cunha L, Kassianides C, et al. Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol. (2021) 6:1036–46. doi: 10.1016/S2468-1253(21)00275
Zhang H-J, Wang Y-Y, Chen C, Lu Y-L, Wang N-J. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999–2016. Chin Med J. (2021) 134:1593–601. doi: 10.1097/CM9.0000000000001513
Xian Y-X, Weng J-P, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. (2021) 134:8–19. doi: 10.1097/CM9.0000000000001263
Xudoykulova F. V. va boshq. THE STRUCTURE, AGE FEATURES, AND FUNCTIONS OF HORMONES //PEDAGOG. – 2023. – Т. 1. – №. 5. – С. 681-688
